Abstract Number TPS788

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)-A\*02 loss of heterozygosity (LOH)



Kristen Spencer\*,1; Salman R Punekar\*,1; Patrick M. Grierson²; Jasmine Mitchell³; Yi Lin⁴; Tiago Biachi de Castria⁵; David B. Zhen6; Peter Vu7; M. Pia Morelli8; Madappa Kundranda9; Oliver Dorigo¹0; David G. Maloney6; Jeffrey Ward²; Cathy Eng<sup>11</sup>; Marcela Maus<sup>12</sup>; Diane M. Simeone<sup>7</sup>; John Welch<sup>13</sup>; Julian R. Molina<sup>4</sup>; William Y. Go<sup>13</sup>; J. Randolph Hecht<sup>14</sup>


¹New York University Langone Health, Perlmutter Cancer Center, New York, NY, USA; ²Washington University in St. Louis, MO, USA; ¹University of California Los Angeles, CA, USA; ¹Mayo Clinic, Rochester, MN, USA; ¹University of California Los Angeles, CA, USA; ¹University of California San Diego, Moores Cancer Center, San Diego, CA, USA; ¹University of California Los Angeles, CA, USA; <sup>8</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>12</sup>Massachusetts General Hospital, Boston, MA, US; <sup>13</sup>A2 Biotherapeutics, Inc., Agoura Hills, CA, USA; <sup>14</sup>UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA, USA; <sup>15</sup>Nassachusetts General Hospital, Boston, MA, US; <sup>16</sup>Nassachusetts General Hospital, Boston, MA, US; <sup>17</sup>Nassachusetts General Hospital, Boston, MA, US; <sup>18</sup>Nassachusetts General Hospital, Boston, MA, US; <sup>19</sup>Nassachusetts General Hospit \*Contributed equally

## BACKGROUND AND STUDY OBJECTIVES

- Implementation of chimeric antigen receptor T-cell (CAR T) therapies in solid tumors has been challenging due to a lack of tumor-specific targets that discriminate cancer from normal cells; for example, CAR T and T-cell receptor fusion therapies targeting mesothelin (MSLN), which is normally expressed in mesothelial cells, but can be upregulated in pancreatic (PANC), colorectal (CRC), ovarian (OVCA), and lung cancers, have been hampered by on-target, off-tumor toxicity, including fatal events [1-3]
- A2B694 is an MSLN-directed Tmod CAR T therapy construct that combines a CAR-activating receptor with a leukocyte immunoglobulin-like receptor-1-based inhibitory receptor (LIR-1; blocker) targeting human leukocyte antigen (HLA)-A\*02 to discriminate tumor from normal cells (Figures 1 and 2) [4,5]
- The activator receptor recognizes MSLN on the surface of both tumor and normal cells
- The blocker receptor recognizes an HLA-A\*02 allele: for patients who are germline HLA-A\*02 heterozygous, loss of the allele may occur in tumor cells, known as loss of heterozygosity (LOH) [6], which can be detected using Tempus next-generation sequencing (NGS; Table 1)
- EVEREST-2 (NCT06051695), the 2nd A2 Bio interventional clinical trial, is a seamless, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B694 in adults with solid tumors


# STUDY RATIONALE

Figure 1. Logic-Gated CAR T With the Goal to Reduce Toxicity: MSLN (Activator) and HLA-A\*02 (Blocker) [4]



HLA, human leukocyte antigen; MSLN, mesothelin.

Figure 2. The Structure of Tmod CAR Ts Expressing an MSLN-Targeted Activator and an HLA-A\*02-Targeted Blocker



The Tmod CAR construct is designed for safety with the LIR-1 inhibitory blocker transcribing before the anti-MSLN activator, minimizing the chance that the activator is expressed without the blocker

β2M shRNA, beta-2-microglobulin short-hairpin RNA; CAR, chimeric antigen receptor; CD, cluster of differentiation; EF1α, elongation factor 1 alpha; HLA, human leukocyte antigen; LIR, leukocyte immunoglobulin-like receptor; MSLN, mesothelin; scFv, single-chain variable fragment; T2A, thosea asigna virus 2A.

# STUDY RATIONALE (CONTINUED)

Table 1. Frequency of HLA-A LOH in Advanced Tumors [8]

	Tempus HLA-A LOH advanced disease real world
Average, % (n)	16.3 (10,867)
Pancreatic cancer, % (n)	19.6 (675)
Colorectal cancer, % (n)	15.6 (1854)
Mesothelioma, % (n)	14.3 (7)
NSCLC, % (n)	23.1 (1915)
Ovarian, fallopian tube, primary peritoneal cancer, % (n)	16.0 (569)

HLA, human leukocyte antigen; LOH, loss of heterozygosity; NSCLC, non-small cell lung cancer.


#### **Nonclinical Studies**

- Nonclinical studies of A2B694 demonstrated improved selectivity and a therapeutic safety window with comparable efficacy to the MSLN-directed M5 CAR T, a cell therapy product that showed clinical efficacy among participants with MSLN-expressing, refractory mesothelioma, non-small cell lung cancer (NSCLC); and OVCA, but resulted in on-target, off-tumor toxicity [2,9]
- Approximately 2 weeks following cell infusion, A2B694 treated NOD scid gamma mice experienced selective regression of tumor grafts (HLA-A\*02-), while "normal" grafts (HLA-A\*02+) continued to grow. Mice treated with MSLN-targeted M5 CAR Ts experienced regressions of both tumor and "normal" grafts (Figure 3)

Figure 3. MSLN Tmod (A2B694) In Vivo Study Demonstrates Efficacy Comparable to M5 CAR T Benchmark

N = 10 mice/group

Xenograft = MS751 cervical




<sup>a</sup>M5 CAR is an MSLN-directed CAR T therapy that was clinically tested in a phase 1 trial [2]. CAR, chimeric antigen receptor; HLA, human leukocyte antigen; MSLN, mesothelin.

## STUDY DESIGN

- EVEREST-2 (NCT06051695) is a first-in-human, phase 1/2, multicenter, open-label, nonrandomized study to evaluate the safety and efficacy of a single-dose of A2B694 Tmod CAR Ts in adults with recurrent unresectable, locally advanced, or metastatic cancers with MSLN expression
- Participants are enrolled in EVEREST-2 through BASECAMP-1 (NCT04981119), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease; enrolled participants undergo leukapheresis and, when clinically appropriate, CAR Ts are manufactured for the EVEREST-2 study (Figure 4)


Figure 4. Study Schema: BASECAMP-1 to EVEREST-2



CAR. chimeric antigen receptor; CRC, colorectal cancer; HLA, human leukocyte antigen; LOH, loss of heterozygosity; MESO, mesothelioma; MSLN, mesothelin; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PANC, pancreatic cancer.

 The phase 1 dose escalation portion of the study employs a Bayesian optimal interval (BOIN) design to assess the safety and tolerability of A2B694 and to determine a recommended phase 2 dose (RP2D; Figure 5); up to 40 participants will be included in the dose escalation

### Figure 5. EVEREST-2 Phase 1 Dose Escalation Study Design



alf dose de-escalation to dose level -2 occurs and dose level -2 is deemed safe, dose escalation of cell dose will be evaluated through dose levels 1-4 with low-dose PCLD. blf toxicities are observed relative to medium-dose PCLD, the Safety Review Team may recommend reduction to low-dose PCLD without de-escalating the A2B694 dose. BOIN, Bayesian optimal interval; DL, dose level; IL, interleukin; PCLD, preconditioning lymphodepletion; RP2D, recommended phase 2 dose.

## STUDY DESIGN (CONTINUED)

#### **Inclusion Criteria**

- Appropriately enrolled in the BASECAMP-1 study, with tissue demonstrating LOH of HLA-A\*02 by NGS (whenever possible from the primary site), successful apheresis and peripheral blood mononuclear cell processing, and with sufficient stored cells available for Tmod therapy
- Histologically confirmed recurrent unresectable, locally advanced, or metastatic PANC, CRC, NSCLC, OVCA, mesothelioma, or other solid tumors with MSLN expression; measurable disease is required with lesions of >1.0 cm by computed tomography
- Received previous required therapy for the appropriate solid tumor disease as described in the protocol
- Has adequate organ function as described in the protocol
- ECOG performance status of 0 to 1
- Life expectancy of ≥3 months
- Willing to comply with study schedule of assessments including long-term safety follow-up

#### Figure 6. EVEREST-2 Study Objectives and Endpoints

### **Objectives**

- Phase 1: Determine the safety and optimal dose of A2B694 (after PCLD) in participants with solid tumor disease
- Phase 2: Determine the further safety and efficacy of A2B694

# **Primary Endpoints**

- Phase 1: Rate of adverse events and dose-limiting toxicities by dose levels; recommended phase 2
- response rate

# **Secondary Endpoints**

 Persistence of A2B694 Serum cytokine analysis

• Phase 2: Overall

PCLD, preconditioning lymphodepletion

## RESULTS

• The first participant was enrolled in EVEREST-2 in April 2024. Dose escalation is ongoing

## SITE LIST

- Banner Health, Gilbert, AZ Principal Investigator (PI): Matthew Ulrickson, MD
- Stanford University, Stanford, CA - PI: Oliver Dorigo, MD, PhD UCSD Moores Cancer Center,
- La Jolla, CA - PI: Sandip Patel, MD UCLA Medical Center, Los Angeles, CA

- PI: J. Randolph Hecht

- Mayo Clinic, Jacksonville, FL PI: Yanyan Lou, MD
- PI: Kedar Kirtane, MD Massachusetts General
- Washington University, St. Louis, MO - PI: Jeffrey Ward, MD, PhD Moffitt Cancer Center, Tampa, FL NYU Langone Medical Center
- PI: Salman Punekar, MD Hospital/Dana-Farber Cancer Institute Fred Hutchinson Cancer Center, - PI: Jong Chul Park, MD Seattle, WA
  - Mayo Clinic, Rochester, MN - PI: Julian Molina, MD, PhD
- PI: David Zhen, MD

New York, NY

## References

- 1. Beatty GL, et al. Gastroenterology. 2018;155:29-32 2. Haas AR, et al. Mol Ther. 2023;31:2309-2325.
- 3. Hong DS, et al. ESMO 2021. Abstract 9590. 4. Hamburger AE, et al. Mol Immunol. 2020;128:298-310.
- 5. DiAndreth B, et al. Clin Immunol. 2022;241:109030. 6. Sandberg ML, et al. Sci Transl Med. 2022:14:eabm0306.
- 7. Borges L, et al. *J Immunol*. 1997;159:5192-5196.
- 8. Hecht J, et al. J Clin Oncol. 2022; 40(4\_suppl):190-190. 9. Tanyi J, et al. *Gynecol Oncol*.
- 2022;166(suppl 1):S164-S165.

### Acknowledgments

- The authors would like to thank the following: Participants and their families and caregivers for being part of the study The screeners, clinical research coordinators, study nurses, data managers, and apheresi
- teams at all the study sites Contributions from others at A2 Bio
- Alexander Kamb, PhD, Founder and Chief Scientific Officer Agnes E. Hamburger, PhD, Chief Operating Officer Talar Tokatlian, PhD, Principal Scientist of Discovery Research
- Diane Manry, PhD, Scientist Discovery Research Breanna Luna, MS, Senior Associate Scientist Discovery Research
- Jason Wang, Associate Scientist Discovery Research Medical writing support was provided by Bio Connections LLC and funded by A2 Bio.
- This study was supported by A2 Bio.